参考文献/References:
[1] Galluzzi L, Vitale I, Abrams JM, et al. Molecular definitions of cell death subroutines:recommendations of the Nomenclature Committee on Cell Death 2012[J]. Cell Death Differ, 2012, 19(1):107-120. DOI:10.1038/cdd.2011.96.
[2] Su Z, Yang Z, Xu Y, et al. Apoptosis, autophagy, necroptosis, and cancer metastasis[J]. Mol Cancer, 2015, 14:48. DOI:10.1186/s12943-015-0321-5.
[3] Jouan-Lanhouet S, Riquet F, Duprez L, et al. Necroptosis, in vivo detection in experimental disease models[J]. Semin Cell Dev Biol, 2014, 35:2-13. DOI:10.1016/j.semcdb.2014.08.010.
[4] Cai Z, Jitkaew S, Zhao J, et al. Plasma membrane translocation of trimerized MLKL protein is required for TNF-induced necroptosis[J]. Nat Cell Biol, 2013, 16(1):55-65. DOI:10.1038/ncb2883.
[5] Dillon CP, Weinlich R, Rodriguez DA, et al. RIPK1 blocks early postnatal lethality mediated by caspase-8 and RIPK3[J]. Cell, 2014, 157(5):1189-1202. DOI:10.1016/j.cell.2014.04.018.
[6] Zhang H, Zhou X, McQuade T, et al. Functional complementation between FADD and RIP1 in embryos and lymphocytes[J]. Nature, 2011, 471(7338):373-376. DOI:10.1038/nature09878.
[7] Huang Z, Wu SQ, Liang Y, et al. RIP1/RIP3 binding to HSV-1 ICP6 initiates necroptosis to restrict virus propagation in mice[J]. Cell Host Microbe, 2015, 17(2):229-242. DOI:10.1016/j.chom.2015. 01.002.
[8] Zhou W, Yuan J. Necroptosis in health and diseases[J]. Semin Cell Dev Biol, 2014, 35:14-23. DOI:10.1016/j.semcdb.2014.07.013.
[9] Vanlangenakker N, Vanden Berghe T, Vandenabeele P. Many sti-muli pull the necrotic trigger, an overview[J]. Cell Death Differ, 2012, 19(1):75-86. DOI:10.1038/cdd.2011.164.
[10] Bertrand MJ, Milutinovic S, Dickson KM, et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination[J]. Mol Cell, 2008, 30(6):689-700.DOI:10.1016/j.molcel.2008.05.014.
[11] Varfolomeev E, Blankenship JW, Wayson SM, et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis[J]. Cell, 2007, 131(4):669-681.DOI:http://dx.doi.org/10.1016/j.cell.2007.10.030.
[12] Moquin DM, McQuade T, Chan FK. CYLD deubiquitinates RIP1 in the TNFα-induced necrosome to facilitate kinase activation and programmed necrosis[J/OL]. PLoS One, 2013, 8(10):e76841[2017-03-22]. https://www.ncbi.nlm.nih.gov/pubmed/?term=24098568.DOI:10.1371/journal.pone.0076841.
[13] Wang L, Du F, Wang X. TNF-α induces two distinct caspase-8 acti-vation pathways[J]. Cell, 2008, 133(4):693-703. DOI:10.1016/j.cell.2008.03.036.
[14] Oberst A, Dillon CP, Weinlich R, et al. Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis[J]. Nature, 2011, 471(7338):363-367. DOI:10.1038/nature09852.
[15] Li J, McQuade T, Siemer AB, et al. The RIP1/RIP3 necrosome forms a functional amyloid signaling complex required for programmed necrosis[J]. Cell, 2012, 150(2):339-350. DOI:10.1016/j.cell.2012. 06.019.
[16] Sun L, Wang H, Wang Z, et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase[J]. Cell, 2012, 148(1-2):213-227. DOI:10.1016/j.cell.2011. 11.031.
[17] Orozco S, Yatim N, Werner MR, et al. RIPK1 both positively and negatively regulates RIPK3 oligomerization and necroptosis[J]. Cell Death Differ, 2014, 21(10):1511-1521. DOI:10.1038/cdd.2014.76.
[18] Kaiser WJ, Sridharan H, Huang C, et al. Toll-like receptor 3-mediated necrosis via TRIF, RIP3, and MLKL[J]. J Biol Chem, 2013, 288(43):31268-31279. DOI:10.1074/jbc.M113.462341.
[19] Upton JW, Kaiser WJ, Mocarski ES. DAI/ZBP1/DLM-1 complexes with RIP3 to mediate virus-induced programmed necrosis that is targeted by murine cytomegalovirus vIRA[J]. Cell Host Microbe, 2012, 11(3):290-297. DOI:10.1016/j.chom.2012.01.016.
[20] McComb S, Cessford E, Alturki NA, et al. Type-I interferon signaling through ISGF3 complex is required for sustained Rip3 activation and necroptosis in macrophages[J/OL]. Proc Natl Acad Sci USA, 2014, 111(31):E3206-E3213[2017-03-22]. https://www.ncbi.nlm.nih.gov/pubmed/?term=25049377.DOI:10.1073/pnas.1407068111.
[21] Mantel F, Frey B, Haslinger S, et al. Combination of ionising irradi-ation and hyperthermia activates programmed apoptotic and necro-tic cell death pathways in human colorectal carcinoma cells[J]. Strahlenther Onkol, 2010, 186(11):587-599. DOI:10.1007/s00066-010-2154-x.
[22] Nehs MA, Lin CI, Kozono DE, et al. Necroptosis is a novel mechanism of radiation-induced cell death in anaplastic thyroid and adrenoco-rtical cancers[J]. Surgery, 2011, 150(6):1032-1039. DOI:10.1016/j.surg. 2011.09.012.
[23] Harberts E, Fishelevich R, Liu J, et al. MyD88 mediates the decision to die by apoptosis or necroptosis after UV irradiation[J]. Innate Immun, 2014, 20(5):529-539. DOI:10.1177/1753425913501706.
[24] Das A, McDonald DG, Dixon-Mah YN, et al. RIP1 and RIP3 complex regulates radiation-induced programmed necrosis in glioblastoma[J]. Tumour Biol, 2016, 37(6):7525-7534. DOI:10.1007/s13277-015-4621-6.
[25] Liu X, Zhou M, Mei L, et al. Key roles of necroptotic factors in promoting tumor growth[J/OL]. Oncotarget, 2016, 7(16):22219-22233[2017-03-22]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008357.DOI:10.18632/oncotarget.7924.
[26] Murphy JM, Czabotar PE, Hildebrand JM, et al. The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism[J]. Immunity, 2013, 39(3):443-453. DOI:10.1016/j.immuni. 2013.06. 018.
[27] Wang H, Sun L, Su L, et al. Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon phospho-rylation by RIP3[J]. Mol Cell, 2014, 54(1):133-146. DOI:10.1016/j.molcel.2014.03.003.
[28] Lalaoui N, Brumatti G. Relevance of necroptosis in cancer[J]. Immunol Cell Biol, 2017, 95(2):137-145. DOI:10.1038/icb.2016.120.
[29] Moriwaki K, Bertin J, Gough PJ, et al. Differential roles of RIPK1 and RIPK3 in TNF-induced necroptosis and chemotherapeutic agent-induced cell death[J/OL]. Cell Death Dis, 2015, 6:e1636[2017-03-22]. DOI:10.1038/cddis.2015.16.
[30] Philipp S, Sosna J, Plenge J, et al. Homoharringtonine, a clinically approved anti-leukemia drug, sensitizes tumor cells for TRAIL-induced necroptosis[J/OL]. Cell Commun Signal, 2015, 13:25[2017-03-22]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4411737/.DOI:10.1186/s12964-015-0103-0.
[31] Wada N, Kawano Y, Fujiwara S, et al. Shikonin, dually functions as a proteasome inhibitor and a necroptosis inducer in multiple myeloma cells[J]. Int J Oncol, 2015, 46(3):963-972. DOI:10.3892/ijo.2014. 2804.
[32] Xu B, Xu M, Tian Y, et al. Matrine induces RIP3-dependent necrop-tosis in cholangiocarcinoma cells[J/OL]. Cell Death Discov, 2017, 3:16096[2017-03-22]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5253620.DOI:10.1038/cddiscovery.2016.96.
[33] Holohan C, Van Schaeybroeck S, Longley DB, et al. Cancer drug resistance:an evolving paradigm[J]. Nat Rev Cancer, 2013, 13(10):714-726. DOI:10.1038/nrc3599.
[34] Han W, Li L, Qiu S, et al. Shikonin circumvents cancer drug resis-tance by induction of a necroptotic death[J]. Mol Cancer Ther, 2007, 6(5):1641-1649. DOI:10.1158/1535-7163.MCT-06-0511.
[35] Bonapace L, Bornhauser BC, Schmitz M, et al. Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance[J]. J Clin Invest, 2010, 120(4):1310-1323. DOI:10.1172/JCI39987.
[36] Laukens B, Jennewein C, Schenk B, et al. Smac mimetic bypasses apoptosis resistance in FADD-or caspase-8-deficient cells by prim-ing for tumor necrosis factor α-induced necroptosis[J]. Neoplasia, 2011, 13(10):971-979. DOI:10.1593/neo.11610.
[37] McCabe KE, Bacos K, Lu D, et al. Triggering necroptosis in cisplatin and IAP antagonist-resistant ovarian carcinoma[J/OL]. Cell Death Dis, 2014, 5:e1496[2017-03-22]. https://www.nature.com/cddis/journal/v5/n10/full/cddis2014448a.html.DOI:10.1038/cddis.2014.448.
[38] Wang Z, Jiang H, Chen S, et al. The mitochondrial phosphatase PGAM5 functions at the convergence point of multiple necrotic death pathways[J]. Cell, 2012, 148(1-2):228-243. DOI:10.1016/j.cell.2011.11.030.
[39] Forbes SA, Bhamra G, Bamford S, et al. The Catalogue of Somatic Mutations in Cancer (COSMIC)[J/OL]. Curr Protoc Hum Genet, 2008[2017-03-22]. https://www.ncbi.nlm.nih.gov/pubmed/?term=18428421.DOI:10.1002/0471142905.hg1011s57.
[40] Wilson WR, Hay MP. Targeting hypoxia in cancer therapy[J]. Nat Rev Cancer, 2011, 11(6):393-410. DOI:10.1038/nrc3064.
[41] Huang CY, Kuo WT, Huang YC, et al. Resistance to hypoxia-induced necroptosis is conferred by glycolytic pyruvate scavenging of mito-chondrial superoxide in colorectal cancer cells[J/OL]. Cell Death Dis, 2013, 4:e622[2017-03-22]. https://www.ncbi.nlm.nih.gov/pubmed/?term=23640464.DOI:10.1038/cddis.2013.149.
相似文献/References:
[1]何燕,苏晋,郑晓霞,等.P-糖蛋白抑制剂在PET显像中的应用研究[J].国际放射医学核医学杂志,2016,40(1):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
He Yan,Su Jin,ZhengXiaoxia,et al.Developing P-glycoprotein inhibitor marked by PET[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
[2]许飞,刘建军,黄钢,等.PET乏氧显像在预测肿瘤乏氧及指导临床治疗中的应用进展[J].国际放射医学核医学杂志,2016,40(1):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
Xu Fei,Liu Jianjun,Huang Gang,et al.The application of hypoxia imaging with PET in predicting tumor hypoxia and guiding clinical therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
[3]陈顺军,程兵.肿瘤细胞凋亡核素显像分子探针研究进展[J].国际放射医学核医学杂志,2016,40(2):149.[doi:10.3760/cma.j.issn.1673-4114.2016.02.013]
Chen Shunjun,Cheng Bing.Progress in molecular probes of radionuclide tumor apoptosis imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):149.[doi:10.3760/cma.j.issn.1673-4114.2016.02.013]
[4]陈晓艳,张江虹,邵春林.STAT3与辐射敏感相关性的研究进展[J].国际放射医学核医学杂志,2016,40(3):191.[doi:10.3760/cma.j.issn.1673-4114.2016.03.007]
Chen Xiaoyan,Jianghong,Shao Chunlin.Research progresses of correlation between STAT3 and radiosensitivity[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):191.[doi:10.3760/cma.j.issn.1673-4114.2016.03.007]
[5]赵舒怡,储小飞,樊赛军.血清肿瘤标志物与肿瘤放疗疗效评估的研究进展[J].国际放射医学核医学杂志,2015,39(5):427.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 018]
zhao shuyi,chu xiaofei,fan saijun..progression of study on serum tumor markers in evaluation of tumor radiotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):427.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 018]
[6]赵徵鑫,翟贺争,张文艺,等.质子重离子治疗肿瘤的进展[J].国际放射医学核医学杂志,2016,40(5):384.[doi:10.3760/cma.j.issn.1673-4114.2016.05.010]
Zhao Zhixin,Zhai Hezheng,Zhang Wenyi,et al.Development of proton heavy ion in tumor therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):384.[doi:10.3760/cma.j.issn.1673-4114.2016.05.010]
[7]任佳忠,李永梅,刘岩,等.99Tcm-MDP骨显像胸部异常放射性摄取的原因分析[J].国际放射医学核医学杂志,2016,40(6):459.[doi:10.3760/cma.j.issn.1673-4114.2016.06.011]
Jiazhong,Li Yongmei,Liu Yan,et al.Reasons for the abnormal 99Tcm-MDP uptake in the thoracic tissue on bone scintigraphy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):459.[doi:10.3760/cma.j.issn.1673-4114.2016.06.011]
[8]马彦云,张辉.磁共振体素内不相干运动扩散加权成像的原理及应用进展[J].国际放射医学核医学杂志,2016,40(6):469.[doi:10.3760/cma.j.issn.1673-4114.2016.06.013]
Ma Yanyun,Zhang Hui.The basic principle and application progress of intravoxel incoherent motion imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):469.[doi:10.3760/cma.j.issn.1673-4114.2016.06.013]
[9]杨卫东,汪静.肿瘤核素靶向治疗新进展[J].国际放射医学核医学杂志,2015,39(1):19.[doi:10.3760/cma.j.issn.1673-4114.2015.01.006]
Yang Weidong,Wang Jing.Advance progress of radionuclide target tumor therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):19.[doi:10.3760/cma.j.issn.1673-4114.2015.01.006]
[10]徐金苹,袁德晓,张江虹,等.辐射诱导的外泌体在肿瘤细胞侵袭转移中的作用[J].国际放射医学核医学杂志,2015,39(2):144.[doi:10.3760/cma.j.issn.1673-4114.2015.02.009]
Xu Jinping,Yuan Dexiao,Zhang Jianghong,et al.The role of radiation-induced exosomes in tumor invasion and metastasis[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):144.[doi:10.3760/cma.j.issn.1673-4114.2015.02.009]